Cancer cachexia: One step ahead

Reviews on Recent Clinical Trials

Volumn 10, Issue 3, 2015, Pages 246-250

  Meriggi, Fausto ^a  

^a Poliambulanza Foundation Hospital   (Italy)

Author keywords

Anamorelin; Cancer cachexia; Cytokines; Multifactorial syndrome

Indexed keywords

ANAMORELIN; ANDROGEN; CANNABIS; CORTICOSTEROID; DEXAMETHASONE; DRONABINOL; ICOSAPENTAENOIC ACID; MEGESTROL ACETATE; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; HYDRAZINE DERIVATIVE; OLIGOPEPTIDE;

ADVANCED CANCER; APPETITE; ARTICLE; BODY MASS; CACHEXIA; CANCER PATIENT; CATABOLISM; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; DIETARY INTAKE; DRUG EFFICACY; DRUG TOLERABILITY; EARLY DIAGNOSIS; EXERCISE; FAT MASS; FOOD INTAKE; HUMAN; INFLAMMATION; LEAN BODY WEIGHT; METABOLISM; MUSCLE MASS; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PRIORITY JOURNAL; REHABILITATION; SARCOPENIA; STARVATION; WEIGHT REDUCTION; CANCER STAGING; COMPLICATION; DISEASE COURSE; FEMALE; MALE; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR INVASION;

CACHEXIA; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; HYDRAZINES; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS; NUTRITIONAL SUPPORT; OLIGOPEPTIDES; PHYSICAL THERAPY MODALITIES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84946042655     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887110666150916141351     Document Type: Article

References (53)

1. Dewys WD, Begg C, Lavin PT. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 491-7.
2. Oberholzer R, Hopkinson JB, Baumann K, et al. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symp Manag 2013; 46: 77-95.
3. Tan CR, Yaffee PM, Jamil LH, et al. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Frontiers Physiol 2014; 5: 1-14.
4. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-95.
5. Blum D, Stene GB, Solheim TS, et al, on behalf of Euro-Impact. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol 2014; 25; 1635-42.
6. Wheelwright S, Darlington AS, Hopkinson JB, et al. A systematic review of health-related quality of life instruments in patients with cancer cachexia. Support Care Cancer 2013; 21: 2625-36.
7. Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 2010; 10: 50.
8. Andreyev HJN, Norman AR, Oates J, et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34: 503-9.
9. Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 2004; 90: 1905-11.
10. Bachmann J, Heiligensetzer M, Krakowski-Roosen H et al. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008; 12: 1193-201.
11. Muscaritoli M, Molfino A, Lucia S, Rossi Fanelli F. Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach. Crit Rev Oncol Hemat 2015; 94: 251-9.
12. Aapro M J, Arends J, Bozzetti F, et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol 2014; 25: 1492-9.
13. Lokireddy S, Wijesoma IW, Bonala S, et al. Myostatin is a novel tumorl factor that induces cancer cachexia. Biochem J 2015; 466: 201.
14. Bilir C, Engin H, Can M, Temi YB, Demirtas D. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. Med Oncol 2015; 32: 497.
15. Blum D, Omlin A, Baracos VE, et al. European Palliative Care Research Collaborative. Cancer cachexia: A systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hemat 2011; 80: 114-44.
16. Narsale AA, Carlson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care 2014; 8: 321-7.
17. Penet M-F, Bhujwalla ZM. Cancer cachexia, recent advances, and future directions. Cancer J 2015; 21: 117-22.
18. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2013; 10: 90-9.
19. Straub RH, Cutolo M, Buttgereit F, Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 2010; 267: 543-60.
20. Nelson K, Walsh D. Management of the anorexia/cachexia syndrome. Cancer Bull 1991; 43: 403-6.
21. Tisdale MJ. Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 1997; 13: 1-7.
22. Devereaux DF, Redgrave TG, Tilton M, et al. Intolerance to administered lipids in tumor bearing animals. Surgery 1984; 100: 292-7.
23. Vlassara H, Spiegel RJ, Daval DS, et al. Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm Metab Res 1986; 18: 698-703.
24. Fearon CH, Glass DJ, Guttridge DC. Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways. Cell Metabolism 2012; 16: 153-66.
25. Argilés JM, López-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999; 19: 223-48.
26. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
27. Douglas E, McMillan D. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev 2014; 40: 685-91.
28. Fouladiun M, Körner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care-correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005; 103: 2189-98.
29. Di Sebastiano KM, Mourtzakis M. A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer. Appl Physiol Nutr Metab 2012; 37: 811-21.
30. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009; 3: 269-75.
31. del Fabbro E. More is better: a multimodality approach to cancer cachexia. Oncologist 2010; 15: 119-21.
32. Balstad TR, Solheim TS, Strasser F, Kaasa S, Bye A. Dietary treatment of weight loss in patients with advanced cancer and cachexia: A systematic literature review. Crit Rev Oncol Hemat 2014; 91: 210-21.
33. Isenring EA, Teleni L. Nutritional counseling and nutritional supplements: a cornerstone of multidisciplinary cancer care for cachectic patients. Curr Opin Supp Palliat Care 2013; 7: 390-95.
34. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase iii, randomized, double-blind, placebocontrolled clinical trial from the cannabis-in-cachexia-study-group. J Clin Oncol 2006; 24: 3394-400.
35. Fearon KCH, Barber MD, Moses AG, et al. Double-blind placebocontrolled, randomized study of Eicosapentaenoic Acid Diester in patients with cancer cachexia. J Clin Oncol 2006; 24: 3401-7.
36. del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of Melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol 2013; 31: 1271-6.
37. Solheim TS, Fearon KC, Blum D, Kaasa S. Non-steroidal antiinflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncologica 2013; 52: 6-17.
38. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33: 1607-9.
39. Loprinzi CL, Ellison NM, Schaid DM, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127-32.
40. Loprinzi CL, Schaid DJ, Dose AM, et al. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993; 11: 152-4.
41. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation for four doses of megestrol acetate as therapy for patient with cancer anorexia and/or cachexia. J Clin Oncol 1993; 11: 792-7.
42. Rowland Jr KM, Loprinzi CL, Shaw EG, et al. Randomized double- blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996; 14: 135-41.
43. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17: 3299-306.
44. Molfino A, Formiconi A, Rossi Fanelli F, et al. Ghrelin: from discovery to cancer cachexia therapy. Curr Opin Clin Nutr Metab Care 2014; 17: 471-6.
45. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 2832-6.
46. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter randomized, double-blind, crossover, pilot study. Support Care Cancer 2013; 21: 129-37.
47. Porporato PE, Filigheddu N, Reano S, et al. Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. J Clin Invest 2013; 123: 611-22.
48. Molfino A, Gioia G, Muscaritoli M. The hunger hormone ghrelin in cachexia. Expert Opin Biol Ther 2013; 13: 465-8.
49. Pietra C, Takeda Y, Tazawa-Ogata N, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle 2014; 5: 329-37.
50. Leblanc TW, Samsa GP, Wolf SP, Locke SC, Cella DF, Abernethy AP. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexiacachexia syndrome (CACS). Support Care Cancer 2015; (Epub ahead of print).
51. Ribaudo JM, Cella D, Hahn EA, et al. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 2000; 9: 1137-46.
52. Temel J, Currow D, Fearon K, et al. Phase III trials of Anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2). In: Proceedings of ASCO 2015 Chicago. J Clin Oncol 2015; 33 9500.
53. Nicolini A, Ferraria P, Masoni MC, et al. Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment. Biomedicine & Pharmacotherapy 2013; 67: 807-17.